Speakers

Eric Cornut
Dr Eric Cornut
Interim Director General at Efpia and Chief Ethics, Compliance and Policy Officer of Novartis
Kathleen Cools
Kathleen Cools
Journalist and host of current affairs programme Terzake at VRT
Maggie De Block 
Dr Maggie De Block
Minister of Social Affairs and Health

Hans-Georg Eichler 
Prof Dr Hans-Georg Eichler
Senior Medical Officer at the European Medicines Agency (EMA)

 

Dr Stefaan Van Der Spiegel
MBA, Head of Sector Substances of Human Origin (SoHO) at the European Commission

Mitchell Silva

Dr Mitchell Silva
CEO & Co-founder at Esperity

Pascal Verdonck

Prof Dr Pascal Verdonck
CEO MedTech Flanders and Professor of Biomedical Engineering at Ghent University

Ward Servaes

Ir Ward Servaes
MBA, CEO & Co-founder at moveUP - Smart Rehab Solutions

Jan Kimpen

Dr Jan Kimpen
Chief Medical Officer at Royal Philips

Pieter Vandervoort

Prof Dr Pieter Vandervoort
Cardiologist at Oost-Limburg Hospital

Marc Noppen

Prof Dr Marc Noppen
Chief Executive Officer at University Hospital Brussels

Frank Rademakers

Prof Dr Frank Rademakers
Chief Medical Technology Officer University Hospitals Leuven

Koenraad Van Renterghem

Prof Dr K.M.L.E. van Renterghem
FEBU, Head of the Urology Department at Jessa Hospital Hasselt, Associate Professor at Hasselt University, and Consultant Urologist at University Hospitals Leuven

Walter Van Dyck
Prof Dr Walter Van Dyck
Director Vlerick Healthcare Management Centre

Piet Dirix 
Dr Piet Dirix
Radiation Oncologist, Iridium Cancer Network, Antwerp

 

Brecht Cardoen
Prof Dr Brecht Cardoen
Head of the MINOZ research centre at Vlerick Business School

 

Ansgar Hebborn

Dr Ansgar Hebborn
Head - Global HTA & Payment Policy at F. Hoffmann - La Roche AG

 
Ingrid Maes
Managing Director & Co-founder at Inovigate, Executive in residence at Vlerick Business School

 

  Alexander Roediger
MBA, Policy Lead Oncology, Europe, Middle East, Africa and Canada (EMAC) at MSD Europe

 

 

Detailed programme Enrol now

Detailed Speaker Info

 Eric Cornut
DR ERIC CORNUT
Interim Director General at Efpia
Chief Ethics, Compliance and Policy Officer of Novartis

Session: Panel member

Eric Cornut earned a Doctoral degree in Law from the University of Basel, Switzerland. He began his career at Novartis’ predecessor company, Ciba-Geigy, in 1989 and played a key role in the global merger of Ciba-Geigy and Sandoz in 1996.

Dr Cornut’s positions with Novartis have included Chief Executive Officer Novartis Netherlands and President and CEO of Novartis France. In his current role, he leads the Integrity & Compliance and Public Affairs functions, where he is responsible for strengthening compliance and public policy for Novartis.

Top

Kathleen Cools

Kathleen Cools
Journalist and host of current affairs programme Terzake at VRT
Session: Plenary debate - Competition: the answer in times of austerity?

Kathleen Cools is one of the VRT News service’s most prominent faces, on both radio and television. She has presented almost all of the major news and current affairs programmes at the public broadcaster. In 2013, she was honoured with a Flemish TV Star as best presenter. Her reputation as an experienced and talented interviewer and moderator is rock solid.

Top

Maggie De Block

DR Maggie De Block
Minister of Social Affairs and Health
Session: Collaborate to Innovate: The Societal Perspective

Maggie De Block is a Belgian politician and member of the Flemish liberal party Open Vld. In February 2015, she was voted the most popular politician in Belgium. She is the Minister of Social Affairs and Health in the Michel Government.

Top

Hans-Georg Eichler

PROF DR HANS-GEORG EICHLER
Senior Medical Officer at the European Medicines Agency (EMA)
Session: Collaborate to Innovate: The Drug Regulator's Perspective

Hans-Georg Eichler, M.D., M.Sc., is the Senior Medical Officer at the European Medicines Agency in London, UK, where he is responsible for coordinating activities between the Agency’s scientific committees and giving advice on scientific and public health issues.

Dr Eichler holds an M.D. degree from Vienna University Medical School and a Master of Science degree in Toxicology from the University of Surrey in Guildford, UK. Prior to joining the European Medicines Agency, Dr Eichler was at the Medical University of Vienna in Austria for 15 years.

His industry experience includes positions at Ciba-Geigy Research Labs (UK) and Outcomes Research at Merck & Co. (USA).

Top



 
DR STEFAAN VAN DER SPIEGEL
MBA, Head of Sector Substances of Human Origin (SoHO) at the European Commission 
Session: Personalized biotech: experiences from transplant medicine

Stefaan Van Der Spiegel coordinates the work of the European Commission's team on Substances of Human Origin (SoHO), including blood, organs and tissues & cells. He joined the Commission in 2004 as policy officer on pricing, reimbursement and access of pharmaceuticals, amongst others managing the European Commission's Pharmaceutical Forum. He started his career as strategy consultant with McKinsey & Co for several actors in the healthcare sector (hospitals, biotech startups, pharmaceutical companies, medical device companies, …). He is trained in medicine (MD) and in business administration (MBA).

Top



Mitchell Silva 
DR MITCHELL SILVA
CEO & Co-founder at Esperity
Session: Co-creation with empowered patients in the entire drug development life cycle

Mitchell Silva is co-founder and CEO of Esperity, a platform for encouraging patients to find peer support and clinical trials and to promote self-tracking. He is also the chair of the Belgian EUPATI national platform and a board member of ReumaNet. Dr Silva is a patient expert, participating in and organising patient partnership programmes that include patient input during the design phase of new patient services.  He holds a PhD degree in bio-engineering from the KULeuven.

Top

Pascal Verdonck

PROF DR PASCAL VERDONCK
CEO MedTech Flanders and Professor of Biomedical Engineering at Ghent University
 
Session: Convergence in the MedTech ecosystem

Pascal Verdonck holds Master of Science Civil Engineering, Master of Business Administration, Master of Science Biomedical Engineering, and PhD degrees, all from Ghent University.

He is a Professor of Medical Technology at Ghent University and a visiting professor at KULeuven. In addition to his position as CEO of MedTech Flanders, Prof Verdonck is also an active member of the board of directors of Acerta, Artevelde University College, AZ Maria Middelares Hospital, OLV Aalst Hospital, Voka Flanders Chamber of Commerce and Industry, and the Belgian Society of Hospital Directors.

Top

Ward Servaes

IR WARD SERVAES
MBA, CEO & Co-founder at moveUP - Smart Rehab Solutions 
Session: Case moveUP: challenges and opportunities in eHealth

Ward Servaes is co-founder and CEO at moveUP cvba, which was founded in November 2015 in Brussels, Belgium.

moveUP offers state-of-the-art rehabilitation services − developed by orthopaedic surgeons, physiotherapists and engineers − for hip and knee surgical patients. moveUP combines objective data from wearable devices with the patient’s subjective well-being to provide a more personalised, faster and painless rehabilitation for a fraction of the cost of traditional methods.

Top

Jan Kimpen

DR JAN KIMPEN
Chief Medical Officer at Royal Philips
Session: Artificial Intelligence-supported diagnostics solution in oncology

Jan Kimpen is Chief Medical Officer at Royal Philips in the Netherlands, where he performs an overall functional leadership role for the company’s clinical innovation, clinical strategy, medical affairs and health economics activities.

A scientist studying the role of the immune system in viral infectious diseases, Dr Kimpen is also an advisor to non-profit as well as profit organisations.

Top

Pieter Vandervoort

Prof Dr PIETER VANDERVOORT
Cardiologist at Oost-Limburg Hospital
Session: Action point 19: mobile health - a first glimpse on the research results of 3 projects within cardiovascular care 

Pieter Vandervoort is a practicing cardiologist at Ziekenhuis Oost-Limburg in Genk, Belgium, and co-founder of the Mobile Health Unit (MHU) at Hasselt University. Trained at the University of Leuven and Massachusetts General Hospital in Boston (US), Dr Vandervoort is pioneering the use of the internet, smartphones and remote monitoring devices to follow up on patients outside the hospital. 

The Mobile Health Unit is a multidisciplinary research group bringing together clinicians, biomedical scientists and engineers to work on several mobile health related research projects in collaboration with hospitals, research institutes, health tech companies and start-ups.

Top

Marc Noppen

Prof Dr MARC NOPPEN
Chief Executive Officer at University Hospital Brussels 
Session: Healthcare 2.0: can have, wanna have, must have?

Marc Noppen is Director of the Academic Hospital of the Vrije Universiteit Brussel. He studied medicine at Hasselt University and the Vrije Universiteit Brussel; and in 2000, he was appointed Head of the Lung Disease Service in the Academic Hospital. Dr Noppen is also a visiting professor at universities in America, Canada and France, and has won several scientific prizes.

Top

Frank Rademakers

Prof Dr FRANK RADEMAKERS
Chief Medical Technology Officer University Hospitals Leuven 
Session: Big Data in Healthcare: Hype of Hope? 

Frank Rademakers is Chief Medical Technology Officer University Hospitals Leuven and Professor of Medicine and Cardiology at the KULeuven. In addition to his medical technology position and teaching responsibilities, he is a Member of the Management Team University Hospitals Leuven and responsible for the cardiac imaging laboratory.

Top

Koenraad Van Renterghem

PROF DR K.M.L.E. VAN RENTERGHEM
FEBU, Head of the Urology Department at Jessa Hospital Hasselt, Associate Professor at Hasselt University, and Consultant Urologist at University Hospitals Leuven 

Session: Opportunities of a trans hospital cross association between 4 different urology departments

K.M.L.E. van Renterghem earned his Medical degree in Surgery and Obstetrics at the K.U. Leuven. He has received special training in neuro-stimulation, urodynamics, male infertility, andrology and impotence, paediatric urology, urologic oncology, and laparoscopic urology.

A member of the Belgian Association of Urology and the Belgian Professional Society of Urology, Dr Renterghem has published widely in the field.

Top

Walter Van Dyck

Prof Dr Walter Van Dyck
Director Vlerick Healthcare Management Centre

Session: Monitor of the track "Competing for access"

Top

Piet Dirix

DR PIET DIRIX
Radiation Oncologist, Iridium Cancer Network, Antwerp
Session: Iridium Cancer Network: networking avant la lettre

Piet Dirix earned a PhD in medical sciences in 2010 (with a thesis on ‘Optimization of IMRT for head and neck cancer’) and graduated as a radiation oncologist in 2012. He currently works in the Iridium Cancer Network, where his focus lies on pelvic genito-urinary (GU) cancers.

The Iridium Cancer Network is a close collaboration among all 7 hospitals in Antwerp, Belgium, in radiation oncology, medical oncology and haematology. The one radiotherapy department treats around 5000 patients per year.

Dr Dirix is also an Associate Professor at Antwerp University. His main research interest is on the use of innovative imaging for radiotherapy planning.

Top

Brecht Cardoen

Prof Dr Brecht Cardoen
Head of the MINOZ research centre at Vlerick Business School

Session: Monitor of the track "Competing for patients"

Top

Ansgar Hebborn 
DR ANSGAR HEBBORN
Head - Global HTA & Payment Policy at F. Hoffmann - La Roche AG
Session: Vlerick Research Project: Industry-payer Collaboration: Where are we in Europe?

Ansgar is Roche Pharma’s Head of HTA & Payment Policy based in Basel, Switzerland. He is a member and active contributor to national and international pharmaceutical policy forums as well as professional associations. He currently represents Roche in relevant industry associations e.g. in EFPIA as a vice-chair of the HTA Working Group. During the past couple of years, Ansgar has taken an active role as advisor and stakeholder representative in various HTA collaboration networks e.g. EUnetHTA and the HTAi Policy Forum Committee. He has  also has been involved in the foundation of other initiatives e.g. the Green Park Collaborative, the HTAi Asia Policy Forum and SwissHTA.

Top

 
INGRID MAES
Managing Director & Co-founder at Inovigate, Executive in residence at Vlerick Business School
Session: Moderator Track 2: Health Tech Convergence

Ingrid Maes is co-Founder and Managing Director of Inovigate, based in Basel (Switzerland) and Antwerp (Belgium). Ingrid has 28 years of experience in the pharmaceutical, medical device and life science sector, and 15 years’ experience in international leadership roles at Alfa Laval, Siemens and PwC. She is a member of various think tanks and advised FDA and EMA on adoption of innovative technologies. Ingrid has a Master in Engineering Sciences - Chemistry & Biotechnology, Medicinal chemistry from the University of Brussels (1989). 

Top

 
ALEXANDER ROEDIGER
MBA, Policy Lead Oncology, Europe, Middle East, Africa and Canada (EMAC) at MSD Europe
Session: Vlerick Research project: Horizon scanning: collaboration between society and the firm setting health priorities

Alexander Roediger, MA and Executive MBA HSG, leads MSD's Oncology Policy in Europe, Middle East, Africa and Canada (EMEAC). In his role he initiates and coordinates regional and national policy initiatives securing patient access and sustainable cancer care. He chairs the EFPIA Oncology Steering Committee and the Healthcare Committee of the American Chamber of Commerce to the EU (AmCham EU).

In his previous roles he was head of the communication and policy department at UNICEF Switzerland and worked in health policy and communications for the largest Swiss health insurance, Helsana. He holds a Master’s degree in Philosophy of the University of Zurich (Switzerland) and an Executive MBA of the University of St. Gallen (Switzerland).

Top

Detailed programme Enrol now

Accreditations
& Rankings

Equis Association of MBAs AACSB Financial Times